Samantha Bosis1, Susanna Esposito2,3. 1. Pediatric Highly Intensive Care Unit, Department of Pathophysiology and Transplantation, Fondazione IRCCS Ca' Granda Ospedale Maggiore Policlinico, Università degli Studi di Milano, Milan, Italy. 2. Pediatric Highly Intensive Care Unit, Department of Pathophysiology and Transplantation, Fondazione IRCCS Ca' Granda Ospedale Maggiore Policlinico, Università degli Studi di Milano, Milan, Italy. susanna.esposito@unimi.it. 3. Pediatric Clinic, Department of Surgical and Biomedical Sciences, Università degli Studi di Perugia, Piazza Menghini 1, 06129, Perugia, Italy. susanna.esposito@unimi.it.
Abstract
PURPOSE OF REVIEW: This review summarizes the current knowledge regarding the role of Enterovirus D68 (EV-D68) in community-acquired pneumonia (CAP) in children. RECENT FINDINGS: EV-D68 is an emergent viral pathogen. Since its first isolation in 1962 in California in four children suffering from CAP and bronchiolitis, EV-D68 has been rarely detected from respiratory specimens. However, recently, EV-D68 infection has raised concerns in the international community because of outbreaks in 2014 in the USA and the increased number of children with EV-D68-associated severe respiratory illnesses, including pneumonia, that have been reported in many other countries around the world. EV-D68 causes severe and life-threatening respiratory diseases in the pediatric population, particularly in children with underlying conditions such as prematurity or chronic diseases. Since no specific treatment or vaccinations are available for EV-D68 infections, greater surveillance as well as the use of sensitive and rapid diagnostic methods are essential to prevent and manage new outbreaks.
PURPOSE OF REVIEW: This review summarizes the current knowledge regarding the role of Enterovirus D68 (EV-D68) in community-acquired pneumonia (CAP) in children. RECENT FINDINGS:EV-D68 is an emergent viral pathogen. Since its first isolation in 1962 in California in four children suffering from CAP and bronchiolitis, EV-D68 has been rarely detected from respiratory specimens. However, recently, EV-D68 infection has raised concerns in the international community because of outbreaks in 2014 in the USA and the increased number of children with EV-D68-associated severe respiratory illnesses, including pneumonia, that have been reported in many other countries around the world. EV-D68 causes severe and life-threatening respiratory diseases in the pediatric population, particularly in children with underlying conditions such as prematurity or chronic diseases. Since no specific treatment or vaccinations are available for EV-D68 infections, greater surveillance as well as the use of sensitive and rapid diagnostic methods are essential to prevent and manage new outbreaks.
Authors: Alexander L Greninger; Samia N Naccache; Kevin Messacar; Anna Clayton; Guixia Yu; Sneha Somasekar; Scot Federman; Doug Stryke; Christopher Anderson; Shigeo Yagi; Sharon Messenger; Debra Wadford; Dongxiang Xia; James P Watt; Keith Van Haren; Samuel R Dominguez; Carol Glaser; Grace Aldrovandi; Charles Y Chiu Journal: Lancet Infect Dis Date: 2015-03-31 Impact factor: 25.071
Authors: Christopher M Oermann; Jennifer E Schuster; Gregory P Conners; Jason G Newland; Rangaraj Selvarangan; Mary Anne Jackson Journal: Ann Am Thorac Soc Date: 2015-05
Authors: Rafal Tokarz; Cadhla Firth; Shabir A Madhi; Stephen R C Howie; Winfred Wu; Amadou Alpha Sall; Saddef Haq; Thomas Briese; W Ian Lipkin Journal: J Gen Virol Date: 2012-06-13 Impact factor: 3.891
Authors: Glen R Abedi; John T Watson; Huong Pham; W Allan Nix; M Steven Oberste; Susan I Gerber Journal: MMWR Morb Mortal Wkly Rep Date: 2015-09-04 Impact factor: 17.586
Authors: Kristine M Wylie; Todd N Wylie; Anthony Orvedahl; Richard S Buller; Brandi N Herter; Vincent Magrini; Richard K Wilson; Gregory A Storch Journal: Emerg Infect Dis Date: 2015-01 Impact factor: 6.883